Cancers are categorized according to the tissue in which they
originated, such as breast, bladder or stomach cancer. But tissues are
composed of different types of cells.
Recently, researchers examined tumor samples of 12 different cancer
types and concluded that the diagnosis would improve in about 10% of
cancer cases if they tumors were defined by the cellular and molecular
features, rather than the tissues in which they tumors originated. This
would mean more accurate diagnosis in about 1 in 10 people.
The researchers reported particularly significant findings in bladder
and breast cancers. At least three different subtypes of bladder cancer
were identified, including one that was nearly identical to a form of
non-small cell lung cancer called lung adenocarcinoma, and another most
similar to squamous-cell cancers of the head and neck and of the lungs.
Bladder cancer patients in treatment have often responded very
differently when treated with the same systemic therapy for their
seemingly identical cancer type, and the new findings may explain why
that is.
The researchers confirmed known differences between two forms of breast
cancers called basal-like and luminal. But they also discovered that
these differences are significant and that basal-like breast cancers,
commonly referred to as triple-negative, are a distinct class of tumor.
Basal-like cancers are highly aggressive and more common among black
and younger women.
Basal-like cancers do arise in the breast but, on the molecular level
they have more in common with ovarian cancers and cancers of
squamous-cell origin than with other subtypes of breast cancer. This is
the first time ever anyone has been able to point to important
molecular features shared by basal breast cancer. They also found that
different cancer types have very similar immune signatures, a factor
that may be relevant clinically with the rise of new immune therapies.
Further research could reveal that as many as 30 to 50 percent of cancers need to be reclassified, according to researchers.
No comments:
Post a Comment